Matthew McClure has been appointed executive vice president and chief medical officer of South San Francisco-based Aligos Therapeutics. He was most recently the chief medical officer of Second Genome. McClure’s experience also includes time at InterMune, which was acquired by Roche in 2014. Preclinical-stage Aligos is developing treatments for liver diseases and viral infections.
Sponsored · Whitepaper
With data from IBM Watson Health, epidemiologists can describe treatment patterns, persistence & adherence to therapy
IBM Watson
From Our Editors · Special Report
Becoming the Cell & Gene Therapy Hub
Sponsored · Whitepaper
CMC in Drug Development and Life Cycle Management
PRA Health Sciences
